{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gonadotrophin-releasing+Hormone+Agonist+%28GnRHa%29",
    "query": {
      "condition": "Gonadotrophin-releasing Hormone Agonist (GnRHa)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 3,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:59:59.570Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00667446",
      "title": "Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Precocious",
        "Leuprolide Acetate",
        "Luteinizing Hormone (LH)",
        "Gonadotrophin-releasing Hormone Agonist (GnRHa)",
        "Tanner Staging",
        "Depot Formulation",
        "Suppression of LH",
        "Central Precocious Puberty (CPP)",
        "Gonadotrophin-releasing Hormone (GnRH)",
        "Lupron",
        "GnRH Analog",
        "Pediatrics Central Precocious Puberty"
      ],
      "interventions": [
        {
          "name": "Leuprolide Acetate 3 Month Depot",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 72,
      "start_date": "2008-12",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2014-01-09",
      "last_synced_at": "2026-05-22T04:59:59.570Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Long Beach, California • Los Angeles, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Greenwood Village",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00667446"
    },
    {
      "nct_id": "NCT05567198",
      "title": "Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Systemic Lupus Erythematosus (Sle)",
        "Primary Ovarian Insufficiency (Poi)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 120 Years · Female only"
      },
      "enrollment_count": 100,
      "start_date": "2023-03-03",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-05-22T04:59:59.570Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05567198"
    },
    {
      "nct_id": "NCT01606709",
      "title": "Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Endometrial Receptivity",
        "Ovarian Hyperstimulation Syndrome"
      ],
      "interventions": [
        {
          "name": "GnRH agonist",
          "type": "DRUG"
        },
        {
          "name": "hCG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UConn Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "33 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 33 Years · Female only"
      },
      "enrollment_count": 7,
      "start_date": "2012-04",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2018-11-21",
      "last_synced_at": "2026-05-22T04:59:59.570Z",
      "location_count": 1,
      "location_summary": "Farmington, Connecticut",
      "locations": [
        {
          "city": "Farmington",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01606709"
    }
  ]
}